Sofinnova Partners

GenSight Biologics S.A. is a clinical-stage biotechnology company based in Paris, France, focused on the discovery and development of gene therapies for retinal degenerative diseases and neurodegenerative disorders of the central nervous system. Founded in 2012, the company utilizes innovative technologies, including mitochondrial targeting sequences and optogenetics, to develop treatments that aim to preserve or restore vision in patients with severe vision impairments. Its lead product candidates include GS010, an AAV2-based gene therapy that is currently undergoing Phase III clinical trials for Leber hereditary optic neuropathy caused by mutations in the ND4 gene, and GS030, which is in Phase I/II trials for retinitis pigmentosa and geographic atrophy associated with dry age-related macular degeneration. GenSight Biologics is also advancing other product candidates in preclinical development targeting various ophthalmic and neurodegenerative conditions.

Inventiva Pharma is a clinical-stage biopharmaceutical company based in France, dedicated to developing oral small molecule therapies aimed at addressing significant unmet medical needs in fibrosis, lysosomal storage disorders, and oncology. The company has established a robust pipeline supported by a proprietary discovery engine and a wholly-owned research and development facility. It possesses an extensive library of molecules and a team with considerable expertise in developing compounds that target nuclear receptors, transcription factors, and epigenetic modulation. Inventiva is advancing clinical candidates, including lanifibranor, which is being developed for non-alcoholic steatohepatitis (NASH), a condition currently lacking approved treatments. Additionally, the company is engaged in a variety of pre-clinical therapy programs, further strengthening its portfolio in the fields of oncology, fibrosis, and rare diseases.

Micropep Technologies is an agricultural biotechnology company founded in 2016 and based in Toulouse, France. The company specializes in the development of non-GMO bioherbicides and biostimulants utilizing its innovative miPEP technology, which harnesses naturally-occurring micro-peptides to regulate gene expression and enhance plant growth. Micropep focuses on four key development programs: germination, flowering, growth, and weed control, aiming to improve agricultural yields while maintaining the integrity of plant DNA. By leveraging the potential of these biomimetic peptides, Micropep seeks to provide effective solutions for managing plant genetics and enhancing resistance to diseases, thereby supporting sustainable farming practices.

Sensorion SA is a biopharmaceutical company based in Montpellier, France, focused on developing innovative therapies for inner ear disorders, particularly hearing loss and vestibular deficits. Founded in 2009, the company is engaged in clinical-stage research, with key products including SENS-111, currently in phase II trials for acute unilateral vestibulopathy, and SENS-401, which is in phase I trials for sudden sensorineural hearing loss. Additionally, Sensorion is advancing SENS-300 in pre-clinical development for inner ear toxicity treatment. The company also collaborates with Cochlear Limited to explore combination therapies for cochlear implant patients, aiming to enhance therapeutic outcomes. Sensorion's commitment to addressing inner ear health positions it as a significant player in the biopharmaceutical landscape.

GenSight Biologics S.A. is a clinical-stage biotechnology company based in Paris, France, focused on the discovery and development of gene therapies for retinal degenerative diseases and neurodegenerative disorders of the central nervous system. Founded in 2012, the company utilizes innovative technologies, including mitochondrial targeting sequences and optogenetics, to develop treatments that aim to preserve or restore vision in patients with severe vision impairments. Its lead product candidates include GS010, an AAV2-based gene therapy that is currently undergoing Phase III clinical trials for Leber hereditary optic neuropathy caused by mutations in the ND4 gene, and GS030, which is in Phase I/II trials for retinitis pigmentosa and geographic atrophy associated with dry age-related macular degeneration. GenSight Biologics is also advancing other product candidates in preclinical development targeting various ophthalmic and neurodegenerative conditions.

GenSight Biologics S.A. is a clinical-stage biotechnology company based in Paris, France, focused on the discovery and development of gene therapies for retinal degenerative diseases and neurodegenerative disorders of the central nervous system. Founded in 2012, the company utilizes innovative technologies, including mitochondrial targeting sequences and optogenetics, to develop treatments that aim to preserve or restore vision in patients with severe vision impairments. Its lead product candidates include GS010, an AAV2-based gene therapy that is currently undergoing Phase III clinical trials for Leber hereditary optic neuropathy caused by mutations in the ND4 gene, and GS030, which is in Phase I/II trials for retinitis pigmentosa and geographic atrophy associated with dry age-related macular degeneration. GenSight Biologics is also advancing other product candidates in preclinical development targeting various ophthalmic and neurodegenerative conditions.

Gradient Denervation Technologies is a medical device company based in Paris, France, founded in 2019. It specializes in the development of an endovascular catheter-based technology designed to treat pulmonary hypertension. The device focuses on performing pulmonary artery denervation, which aims to reduce pulmonary vascular resistance and enhance cardiovascular hemodynamics. This innovative approach offers a minimally invasive solution for managing pulmonary hypertension and is built upon prior research and intellectual property developed at Stanford University. The company aims to provide the healthcare sector with a device that delivers consistent and long-lasting results for patients suffering from this condition.

Inventiva Pharma is a clinical-stage biopharmaceutical company based in France, dedicated to developing oral small molecule therapies aimed at addressing significant unmet medical needs in fibrosis, lysosomal storage disorders, and oncology. The company has established a robust pipeline supported by a proprietary discovery engine and a wholly-owned research and development facility. It possesses an extensive library of molecules and a team with considerable expertise in developing compounds that target nuclear receptors, transcription factors, and epigenetic modulation. Inventiva is advancing clinical candidates, including lanifibranor, which is being developed for non-alcoholic steatohepatitis (NASH), a condition currently lacking approved treatments. Additionally, the company is engaged in a variety of pre-clinical therapy programs, further strengthening its portfolio in the fields of oncology, fibrosis, and rare diseases.

GenSight Biologics S.A. is a clinical-stage biotechnology company based in Paris, France, focused on the discovery and development of gene therapies for retinal degenerative diseases and neurodegenerative disorders of the central nervous system. Founded in 2012, the company utilizes innovative technologies, including mitochondrial targeting sequences and optogenetics, to develop treatments that aim to preserve or restore vision in patients with severe vision impairments. Its lead product candidates include GS010, an AAV2-based gene therapy that is currently undergoing Phase III clinical trials for Leber hereditary optic neuropathy caused by mutations in the ND4 gene, and GS030, which is in Phase I/II trials for retinitis pigmentosa and geographic atrophy associated with dry age-related macular degeneration. GenSight Biologics is also advancing other product candidates in preclinical development targeting various ophthalmic and neurodegenerative conditions.

Sensorion SA is a biopharmaceutical company based in Montpellier, France, focused on developing innovative therapies for inner ear disorders, particularly hearing loss and vestibular deficits. Founded in 2009, the company is engaged in clinical-stage research, with key products including SENS-111, currently in phase II trials for acute unilateral vestibulopathy, and SENS-401, which is in phase I trials for sudden sensorineural hearing loss. Additionally, Sensorion is advancing SENS-300 in pre-clinical development for inner ear toxicity treatment. The company also collaborates with Cochlear Limited to explore combination therapies for cochlear implant patients, aiming to enhance therapeutic outcomes. Sensorion's commitment to addressing inner ear health positions it as a significant player in the biopharmaceutical landscape.

TISSIUM is a medical device company headquartered in Paris, France, focused on the development and commercialization of innovative biodegradable sealants and adhesives for surgical wound closure, particularly in minimally invasive procedures. The company's products are designed to be non-toxic, provide strong adhesion to tissues, and enable rapid wound closure in the body's dynamic environments. TISSIUM leverages advanced research and intellectual property from renowned laboratories, including those of Robert Langer at MIT and Jeff Karp at Brigham and Women’s Hospital. Its technology platform includes a proprietary family of fully biosynthetic, biomorphic, and programmable polymers, which are tailored for tissue reconstruction across various clinical applications. Founded in 2013, TISSIUM is supported by leading healthcare investors and aims to address unmet clinical needs through its groundbreaking approach to wound management.

Abivax is a clinical-stage biotechnology company based in France, dedicated to developing innovative therapeutics that leverage the body's natural immune mechanisms to treat patients with autoimmune diseases, viral infections, and cancer. The company's primary focus is on chronic inflammatory diseases, particularly inflammatory bowel diseases such as ulcerative colitis and Crohn's disease. Abivax is currently evaluating its leading drug candidate, obefazimod, in Phase 3 clinical trials aimed at addressing moderately to severely active ulcerative colitis. Through its drug development platforms, Abivax strives to deliver novel and effective treatments to patients with significant unmet medical needs in these therapeutic areas.

Abivax is a clinical-stage biotechnology company based in France, dedicated to developing innovative therapeutics that leverage the body's natural immune mechanisms to treat patients with autoimmune diseases, viral infections, and cancer. The company's primary focus is on chronic inflammatory diseases, particularly inflammatory bowel diseases such as ulcerative colitis and Crohn's disease. Abivax is currently evaluating its leading drug candidate, obefazimod, in Phase 3 clinical trials aimed at addressing moderately to severely active ulcerative colitis. Through its drug development platforms, Abivax strives to deliver novel and effective treatments to patients with significant unmet medical needs in these therapeutic areas.

Micropep Technologies is an agricultural biotechnology company founded in 2016 and based in Toulouse, France. The company specializes in the development of non-GMO bioherbicides and biostimulants utilizing its innovative miPEP technology, which harnesses naturally-occurring micro-peptides to regulate gene expression and enhance plant growth. Micropep focuses on four key development programs: germination, flowering, growth, and weed control, aiming to improve agricultural yields while maintaining the integrity of plant DNA. By leveraging the potential of these biomimetic peptides, Micropep seeks to provide effective solutions for managing plant genetics and enhancing resistance to diseases, thereby supporting sustainable farming practices.

TISSIUM is a medical device company headquartered in Paris, France, focused on the development and commercialization of innovative biodegradable sealants and adhesives for surgical wound closure, particularly in minimally invasive procedures. The company's products are designed to be non-toxic, provide strong adhesion to tissues, and enable rapid wound closure in the body's dynamic environments. TISSIUM leverages advanced research and intellectual property from renowned laboratories, including those of Robert Langer at MIT and Jeff Karp at Brigham and Women’s Hospital. Its technology platform includes a proprietary family of fully biosynthetic, biomorphic, and programmable polymers, which are tailored for tissue reconstruction across various clinical applications. Founded in 2013, TISSIUM is supported by leading healthcare investors and aims to address unmet clinical needs through its groundbreaking approach to wound management.

Micropep Technologies is an agricultural biotechnology company founded in 2016 and based in Toulouse, France. The company specializes in the development of non-GMO bioherbicides and biostimulants utilizing its innovative miPEP technology, which harnesses naturally-occurring micro-peptides to regulate gene expression and enhance plant growth. Micropep focuses on four key development programs: germination, flowering, growth, and weed control, aiming to improve agricultural yields while maintaining the integrity of plant DNA. By leveraging the potential of these biomimetic peptides, Micropep seeks to provide effective solutions for managing plant genetics and enhancing resistance to diseases, thereby supporting sustainable farming practices.

GenSight Biologics S.A. is a clinical-stage biotechnology company based in Paris, France, focused on the discovery and development of gene therapies for retinal degenerative diseases and neurodegenerative disorders of the central nervous system. Founded in 2012, the company utilizes innovative technologies, including mitochondrial targeting sequences and optogenetics, to develop treatments that aim to preserve or restore vision in patients with severe vision impairments. Its lead product candidates include GS010, an AAV2-based gene therapy that is currently undergoing Phase III clinical trials for Leber hereditary optic neuropathy caused by mutations in the ND4 gene, and GS030, which is in Phase I/II trials for retinitis pigmentosa and geographic atrophy associated with dry age-related macular degeneration. GenSight Biologics is also advancing other product candidates in preclinical development targeting various ophthalmic and neurodegenerative conditions.

Enthera is an Italian biotechnology startup established in October 2016 by BiovelocITA, Professor Paolo Fiorina, and Dr. Francesca D'Addio. The company specializes in developing biotherapeutics aimed at treating autoimmune disorders, with a focus on type 1 diabetes and inflammatory bowel disease. Enthera's pipeline targets key pathways involved in cell apoptosis in the gut, pancreas, and other organs to combat these intractable conditions effectively.

Pixium Vision SA is a bioelectronics company based in Paris, France, focused on developing innovative implantable medical devices aimed at restoring vision for individuals blinded by the degeneration of photoreceptor cells in the retina. The company’s flagship product, the PRIMA System, is a bionic vision system designed to improve visual acuity and enhance the independence of patients. Pixium Vision also works on the Intelligent Retinal Implantable System (IRIS1), which is currently undergoing clinical trials, and is developing two subsequent generations, IRIS2 and IRIS3, each designed to provide improved visual capabilities through advanced technologies. Founded in 2011 as a spin-out from the Vision Institute and Université Pierre et Marie Curie, Pixium collaborates with prestigious institutions such as Stanford University and Moorfields Eye Hospital to further its research and development efforts in retinal implant systems.

Epsilen Bio Srl is a biotechnology company based in Milan, Italy, specializing in the development of transformative therapies for patients with underserved medical conditions. Founded in December 2019, the company focuses on genomic epigenetic silencing, a technique aimed at stably silencing genes that contribute to various pathological processes. By leveraging this innovative approach, Epsilen Bio aims to provide new therapeutic options that address significant gaps in current medical treatments, ultimately enhancing patient care and outcomes.

Inventiva Pharma is a clinical-stage biopharmaceutical company based in France, dedicated to developing oral small molecule therapies aimed at addressing significant unmet medical needs in fibrosis, lysosomal storage disorders, and oncology. The company has established a robust pipeline supported by a proprietary discovery engine and a wholly-owned research and development facility. It possesses an extensive library of molecules and a team with considerable expertise in developing compounds that target nuclear receptors, transcription factors, and epigenetic modulation. Inventiva is advancing clinical candidates, including lanifibranor, which is being developed for non-alcoholic steatohepatitis (NASH), a condition currently lacking approved treatments. Additionally, the company is engaged in a variety of pre-clinical therapy programs, further strengthening its portfolio in the fields of oncology, fibrosis, and rare diseases.

GenSight Biologics S.A. is a clinical-stage biotechnology company based in Paris, France, focused on the discovery and development of gene therapies for retinal degenerative diseases and neurodegenerative disorders of the central nervous system. Founded in 2012, the company utilizes innovative technologies, including mitochondrial targeting sequences and optogenetics, to develop treatments that aim to preserve or restore vision in patients with severe vision impairments. Its lead product candidates include GS010, an AAV2-based gene therapy that is currently undergoing Phase III clinical trials for Leber hereditary optic neuropathy caused by mutations in the ND4 gene, and GS030, which is in Phase I/II trials for retinitis pigmentosa and geographic atrophy associated with dry age-related macular degeneration. GenSight Biologics is also advancing other product candidates in preclinical development targeting various ophthalmic and neurodegenerative conditions.

TISSIUM is a medical device company headquartered in Paris, France, focused on the development and commercialization of innovative biodegradable sealants and adhesives for surgical wound closure, particularly in minimally invasive procedures. The company's products are designed to be non-toxic, provide strong adhesion to tissues, and enable rapid wound closure in the body's dynamic environments. TISSIUM leverages advanced research and intellectual property from renowned laboratories, including those of Robert Langer at MIT and Jeff Karp at Brigham and Women’s Hospital. Its technology platform includes a proprietary family of fully biosynthetic, biomorphic, and programmable polymers, which are tailored for tissue reconstruction across various clinical applications. Founded in 2013, TISSIUM is supported by leading healthcare investors and aims to address unmet clinical needs through its groundbreaking approach to wound management.

Inventiva Pharma is a clinical-stage biopharmaceutical company based in France, dedicated to developing oral small molecule therapies aimed at addressing significant unmet medical needs in fibrosis, lysosomal storage disorders, and oncology. The company has established a robust pipeline supported by a proprietary discovery engine and a wholly-owned research and development facility. It possesses an extensive library of molecules and a team with considerable expertise in developing compounds that target nuclear receptors, transcription factors, and epigenetic modulation. Inventiva is advancing clinical candidates, including lanifibranor, which is being developed for non-alcoholic steatohepatitis (NASH), a condition currently lacking approved treatments. Additionally, the company is engaged in a variety of pre-clinical therapy programs, further strengthening its portfolio in the fields of oncology, fibrosis, and rare diseases.

Abivax is a clinical-stage biotechnology company based in France, dedicated to developing innovative therapeutics that leverage the body's natural immune mechanisms to treat patients with autoimmune diseases, viral infections, and cancer. The company's primary focus is on chronic inflammatory diseases, particularly inflammatory bowel diseases such as ulcerative colitis and Crohn's disease. Abivax is currently evaluating its leading drug candidate, obefazimod, in Phase 3 clinical trials aimed at addressing moderately to severely active ulcerative colitis. Through its drug development platforms, Abivax strives to deliver novel and effective treatments to patients with significant unmet medical needs in these therapeutic areas.

GenSight Biologics S.A. is a clinical-stage biotechnology company based in Paris, France, focused on the discovery and development of gene therapies for retinal degenerative diseases and neurodegenerative disorders of the central nervous system. Founded in 2012, the company utilizes innovative technologies, including mitochondrial targeting sequences and optogenetics, to develop treatments that aim to preserve or restore vision in patients with severe vision impairments. Its lead product candidates include GS010, an AAV2-based gene therapy that is currently undergoing Phase III clinical trials for Leber hereditary optic neuropathy caused by mutations in the ND4 gene, and GS030, which is in Phase I/II trials for retinitis pigmentosa and geographic atrophy associated with dry age-related macular degeneration. GenSight Biologics is also advancing other product candidates in preclinical development targeting various ophthalmic and neurodegenerative conditions.

Enthera is an Italian biotechnology startup established in October 2016 by BiovelocITA, Professor Paolo Fiorina, and Dr. Francesca D'Addio. The company specializes in developing biotherapeutics aimed at treating autoimmune disorders, with a focus on type 1 diabetes and inflammatory bowel disease. Enthera's pipeline targets key pathways involved in cell apoptosis in the gut, pancreas, and other organs to combat these intractable conditions effectively.

Inventiva Pharma is a clinical-stage biopharmaceutical company based in France, dedicated to developing oral small molecule therapies aimed at addressing significant unmet medical needs in fibrosis, lysosomal storage disorders, and oncology. The company has established a robust pipeline supported by a proprietary discovery engine and a wholly-owned research and development facility. It possesses an extensive library of molecules and a team with considerable expertise in developing compounds that target nuclear receptors, transcription factors, and epigenetic modulation. Inventiva is advancing clinical candidates, including lanifibranor, which is being developed for non-alcoholic steatohepatitis (NASH), a condition currently lacking approved treatments. Additionally, the company is engaged in a variety of pre-clinical therapy programs, further strengthening its portfolio in the fields of oncology, fibrosis, and rare diseases.

Micropep Technologies is an agricultural biotechnology company founded in 2016 and based in Toulouse, France. The company specializes in the development of non-GMO bioherbicides and biostimulants utilizing its innovative miPEP technology, which harnesses naturally-occurring micro-peptides to regulate gene expression and enhance plant growth. Micropep focuses on four key development programs: germination, flowering, growth, and weed control, aiming to improve agricultural yields while maintaining the integrity of plant DNA. By leveraging the potential of these biomimetic peptides, Micropep seeks to provide effective solutions for managing plant genetics and enhancing resistance to diseases, thereby supporting sustainable farming practices.

Aledia SA, established in 2011, specializes in the development and manufacturing of light-emitting diodes (LEDs). The company's proprietary technology involves a 3D architecture using gallium-nitride-on-silicon microwires, enabling cost-effective production of LED chips at 25% the cost of traditional planar LED chips. Aledia's products cater to general lighting, automotive, and display applications, with a focus on mobile displays and microdisplays for AR/VR devices. Headquartered in Grenoble, France, the company has subsidiaries in Malacca, Malaysia, and Palo Alto, California.

TISSIUM is a medical device company headquartered in Paris, France, focused on the development and commercialization of innovative biodegradable sealants and adhesives for surgical wound closure, particularly in minimally invasive procedures. The company's products are designed to be non-toxic, provide strong adhesion to tissues, and enable rapid wound closure in the body's dynamic environments. TISSIUM leverages advanced research and intellectual property from renowned laboratories, including those of Robert Langer at MIT and Jeff Karp at Brigham and Women’s Hospital. Its technology platform includes a proprietary family of fully biosynthetic, biomorphic, and programmable polymers, which are tailored for tissue reconstruction across various clinical applications. Founded in 2013, TISSIUM is supported by leading healthcare investors and aims to address unmet clinical needs through its groundbreaking approach to wound management.

CelluComp Ltd. is a material science company based in Burntisland, United Kingdom, specializing in the development and commercialization of biobased materials derived from food processing industry waste streams. Founded in 2004, the company produces Curran, a high-performance material made from nano-cellulose fibers extracted from root vegetables. CelluComp offers a range of products, including Curran paste, slurry, and powders, which are suitable for various applications such as paints, coatings, paper, personal care, and construction materials. Its innovative offerings serve multiple industries and aim to provide environmentally sustainable alternatives by utilizing non-hydrocarbon feedstocks. The company distributes its products across several countries, including the United Kingdom, Germany, and several nations in Europe and the Middle East.

ENYO Pharma SA is a clinical-stage biopharmaceutical company based in Lyon, France, founded in 2014 by scientists from the Infectiology Research Center. The company focuses on drug discovery and development for the treatment of acute and chronic viral infections, utilizing a unique platform to identify intracellular therapeutic targets and molecules. ENYO Pharma is developing a pipeline of drug candidates addressing various indications, including hepatitis B virus, nonalcoholic steatohepatitis, and oncology. Its lead compound, EYP001, is designed to modulate specific nuclear receptors, aiming to reduce viral reservoirs and inhibit harmful viral protein expression. The company is also advancing EYP002 through preclinical studies. ENYO Pharma collaborates closely with established research institutions and aims to conduct its molecules into Phase II clinical trials, striving to become a global leader in antiviral therapeutics.

Aledia SA, established in 2011, specializes in the development and manufacturing of light-emitting diodes (LEDs). The company's proprietary technology involves a 3D architecture using gallium-nitride-on-silicon microwires, enabling cost-effective production of LED chips at 25% the cost of traditional planar LED chips. Aledia's products cater to general lighting, automotive, and display applications, with a focus on mobile displays and microdisplays for AR/VR devices. Headquartered in Grenoble, France, the company has subsidiaries in Malacca, Malaysia, and Palo Alto, California.

Twenga, established in 2006, is a London-based online shopping search platform that connects over 4000 clients across 15 countries with a diverse range of products. It offers services including traffic acquisition, price comparison, and international exposure, helping advertisers enhance their performance and automate investments. With over 120 employees across France, Germany, and the UK, Twenga facilitates the discovery of products across categories like fashion, homeware, and sports, enabling users to find and compare products at competitive prices.

CelluComp Ltd. is a material science company based in Burntisland, United Kingdom, specializing in the development and commercialization of biobased materials derived from food processing industry waste streams. Founded in 2004, the company produces Curran, a high-performance material made from nano-cellulose fibers extracted from root vegetables. CelluComp offers a range of products, including Curran paste, slurry, and powders, which are suitable for various applications such as paints, coatings, paper, personal care, and construction materials. Its innovative offerings serve multiple industries and aim to provide environmentally sustainable alternatives by utilizing non-hydrocarbon feedstocks. The company distributes its products across several countries, including the United Kingdom, Germany, and several nations in Europe and the Middle East.

Pixium Vision SA is a bioelectronics company based in Paris, France, focused on developing innovative implantable medical devices aimed at restoring vision for individuals blinded by the degeneration of photoreceptor cells in the retina. The company’s flagship product, the PRIMA System, is a bionic vision system designed to improve visual acuity and enhance the independence of patients. Pixium Vision also works on the Intelligent Retinal Implantable System (IRIS1), which is currently undergoing clinical trials, and is developing two subsequent generations, IRIS2 and IRIS3, each designed to provide improved visual capabilities through advanced technologies. Founded in 2011 as a spin-out from the Vision Institute and Université Pierre et Marie Curie, Pixium collaborates with prestigious institutions such as Stanford University and Moorfields Eye Hospital to further its research and development efforts in retinal implant systems.

Aledia SA, established in 2011, specializes in the development and manufacturing of light-emitting diodes (LEDs). The company's proprietary technology involves a 3D architecture using gallium-nitride-on-silicon microwires, enabling cost-effective production of LED chips at 25% the cost of traditional planar LED chips. Aledia's products cater to general lighting, automotive, and display applications, with a focus on mobile displays and microdisplays for AR/VR devices. Headquartered in Grenoble, France, the company has subsidiaries in Malacca, Malaysia, and Palo Alto, California.

ABIONYX Pharma SA is a French biopharmaceutical company established in 2005, currently based in Labege. It specializes in the discovery and development of therapies targeting high-density lipoprotein (HDL) for treating cardiovascular and metabolic diseases. The company's primary focus is on developing HDL mimetics to rapidly regress atherosclerotic plaque in high-risk patients. Its lead product candidate, CER-001, is a Phase II clinical trial asset designed to mimic the properties of pre-beta HDL for treating post-acute coronary syndrome patients and familial primary hypoalphalipoproteinemia patients. Additionally, ABIONYX Pharma has another drug candidate, CER-209, in Phase I trials for metabolic diseases and liver-related conditions such as atherosclerosis and non-alcoholic steato-hepatitis.

QuesCom S.A. is a company based in Sophia Antipolis, France, specializing in the design and manufacture of internet telecommunication systems. Founded in 1999, QuesCom develops a range of products including business communication management portals, GSM gateways, SIM servers, and mobile call servers. The company also offers VoIP technology and network management software, catering to the needs of enterprises and service providers. Through partnerships with leading telecommunications firms, QuesCom aims to enhance communication solutions and streamline business operations.

Sensitive Object SA is a company specializing in the development of electronic products and touch-interface technology. Founded in 2003 and headquartered in Boulogne Billancourt, France, with additional operations in Paris and Singapore, the company focuses on a diverse range of applications including touch screens, consumer electronics, computing, outdoor interactive solutions, access control, home automation, healthcare, industrial control, and interactive digital advertising. Its product offerings encompass touch screens, peripherals, and control panels designed to enhance user interaction across various industries.

EOS is a biopharmaceutical company committed to the development of novel medicines for the treatment of cancer.EOS S.p.A. was founded in June 2006 by Silvano Spinelli, Gabriella Camboni, and Ennio Cavalletti along with Jacques Theurillat. Company’s operations were seed and further financed by founders and by Sofinnova Partners since its inception. EOS is a privately held organization headquartered in Via Monte di Pietà, 1/A, Milano, Italy.

blueKiwi Software SA specializes in providing enterprise social software tailored for financial firms, high-tech organizations, and professional services agencies. The company's flagship products include blueKiwi 2009, designed for people-centric organizations to foster social networks and collaborative environments among partners, customers, and colleagues, and blueKiwi Pro, which caters specifically to small and medium businesses. In addition to its software solutions, blueKiwi offers strategic consulting and technical services to enhance client operations. The company operates primarily in France and the United Kingdom.

Streamezzo S.A. is a Paris-based company that specializes in developing mobile media products and solutions tailored for telecom operators, broadcasters, media companies, content providers, and service providers. Founded in 2004, the company offers a comprehensive suite of products including the Rich Media Software Suite, which features tools for mobile users to access interactive services such as Mobile TV, widgets, and multimedia content. Its offerings encompass the Rich Media Client for accessing media services, the Rich Media Server for deploying these services, and an integrated multimedia authoring suite known as Workbench. Additionally, Streamezzo provides various solutions like Interactive Mobile TV, Music Jukebox for music downloads, and tools for mobile marketing and user engagement. The company also delivers professional services to assist clients in managing and customizing their mobile media offerings effectively.

Neosens SA is a company focused on designing and developing advanced sensor solutions and technologies for monitoring and controlling the quality of water and industrial liquids. Established in 2001 and headquartered in Labege, France, Neosens specializes in microelectronic sensors that measure dissolved oxygen levels and monitor fouling in various liquid environments. Its products find applications in diverse sectors, including cooling systems, heat exchangers, potable and ultra-pure water, industrial boilers, and industries such as food and beverage, pharmaceuticals, pulp and paper, oil, gas, and petrochemicals. Neosens aims to enhance environmental monitoring and process efficiency through its innovative sensor technologies.

Qosmos SA, founded in 2000 and headquartered in Paris, France, specializes in embedded deep packet inspection (DPI) technologies for internet protocol traffic classification and network intelligence. The company offers a range of solutions, including ixEngine, a comprehensive software development kit that provides tools for decoding, protocol plugins, and real-time traffic flow classification. Its technology is applicable in various domains such as lawful interception, network protection, regulatory compliance, and content-based billing. Qosmos also develops solutions for virtual network functions and provides application classification and metadata extraction tailored for telecommunications and enterprise developers. With a focus on transforming networks into intelligent information sources, Qosmos enables users to analyze data traffic while supporting applications ranging from security to performance optimization. The company maintains additional offices in London, Silicon Valley, Tokyo, and Singapore and operates as a subsidiary of Enea AB.

Filao publishes, develops, and distributes java based mobile games and java mobile gaming technologies for mass market mobile devices. It specializes in embedded java technologies, wireless games, and entertainment applications. The company serves mobile operators and PDA and handset manufacturers. It distributes its products through shipped, over the air, online, and specialized retail outlets. The company was founded in 2000 as InfraWorlds SA and changed its name to Filao in 2005. Filao is based in Paris, France. As of May 10, 2007, Filao is a subsidiary of Zenops SA.

Neosens SA is a company focused on designing and developing advanced sensor solutions and technologies for monitoring and controlling the quality of water and industrial liquids. Established in 2001 and headquartered in Labege, France, Neosens specializes in microelectronic sensors that measure dissolved oxygen levels and monitor fouling in various liquid environments. Its products find applications in diverse sectors, including cooling systems, heat exchangers, potable and ultra-pure water, industrial boilers, and industries such as food and beverage, pharmaceuticals, pulp and paper, oil, gas, and petrochemicals. Neosens aims to enhance environmental monitoring and process efficiency through its innovative sensor technologies.

Inside Secure, established in 1995 and headquartered in Aix en Provence, France, is a fabless semiconductor company specializing in open-standard contactless payment and near field communication (NFC) solutions. It offers a range of products, including contactless reader interface chips, NFC interface circuits, payment platforms, and memory chips, catering to smart cards, mobile phones, and POS devices. The company also provides professional services such as application development and system integration. Its clients include payment card manufacturers, mobile phone producers, systems integrators, and financial institutions. Additionally, Inside Secure acquired MePIN, a white-label strong authentication platform, expanding its offerings to include secure online identity and payment services.

Fovea Pharmaceuticals is a French biopharmaceutical company established in 2005, specializing in the discovery and development of drugs for ocular diseases. Based in Paris, Fovea focuses on creating innovative treatments for various eye conditions, including allergic conjunctivitis, hereditary angioedema, diabetic macular edema, and retinitis pigmentosa. The company's key products include FOV1101 Prednisporin, FOV2302, FOV2304, and FOV2501, which address a range of ocular disorders and associated complications. As of October 2009, Fovea operates as a subsidiary of Sanofi, enhancing its capabilities to deliver effective therapies for vision-related health issues.

Streamezzo S.A. is a Paris-based company that specializes in developing mobile media products and solutions tailored for telecom operators, broadcasters, media companies, content providers, and service providers. Founded in 2004, the company offers a comprehensive suite of products including the Rich Media Software Suite, which features tools for mobile users to access interactive services such as Mobile TV, widgets, and multimedia content. Its offerings encompass the Rich Media Client for accessing media services, the Rich Media Server for deploying these services, and an integrated multimedia authoring suite known as Workbench. Additionally, Streamezzo provides various solutions like Interactive Mobile TV, Music Jukebox for music downloads, and tools for mobile marketing and user engagement. The company also delivers professional services to assist clients in managing and customizing their mobile media offerings effectively.

VoluBill S.A. is a provider of real-time monitoring, control, and charging software tailored for communication providers. Founded in 2001 and based in Montbonnot Saint Martin, France, with additional offices in Europe and Asia, the company specializes in solutions for fixed, mobile, and fixed mobile convergent operators. VoluBill's product offerings include CHARGE-IT, which facilitates real-time on-the-network convergent charging and control for data services; CHARGE-IT Service Controller, a platform for network charging, control, and policy enforcement; and CHARGE-IT Dynamic Charging Platform, which supports various charging models such as pre-pay, post-pay, and now-pay for data services.

Purple Labs SA is a software development company specializing in mobile Linux solutions for real-time operating systems and Linux-based mobile devices. Founded in 2001 and headquartered in Le Bourget du Lac, France, the company provides a comprehensive software suite known as The Mobile Linux Platform, designed to assist manufacturers in developing mobile feature phones. This suite includes an application suite tailored for 3G feature phones, as well as browser and messaging applications. Additionally, Purple Labs offers the Purple Magic, a 3G Linux feature phone that supports video telephony, music playback, high-speed internet browsing, and video streaming. The company also provides services such as application integration and development, customization of Linux support packages, hardware design, and product industrialization. With a presence in various countries including the United States, China, and South Korea, Purple Labs aims to help phone manufacturers transition from legacy operating systems to flexible and scalable Linux platforms, enabling them to meet market demands efficiently.

Inside Secure, established in 1995 and headquartered in Aix en Provence, France, is a fabless semiconductor company specializing in open-standard contactless payment and near field communication (NFC) solutions. It offers a range of products, including contactless reader interface chips, NFC interface circuits, payment platforms, and memory chips, catering to smart cards, mobile phones, and POS devices. The company also provides professional services such as application development and system integration. Its clients include payment card manufacturers, mobile phone producers, systems integrators, and financial institutions. Additionally, Inside Secure acquired MePIN, a white-label strong authentication platform, expanding its offerings to include secure online identity and payment services.

Diatos is a biopharmaceutical company founded in 1999 and headquartered in Paris, France with two subsidiaries in Leuven, Belgium and in the San Francisco Bay Area, USA. Diatos is focused on the research, development and marketing of new versions of existing anti-cancer chemotherapeutic drugs with enhanced tumor targeting or improved biodistribution. Diatos has built its portfolio of drugs and drug candidates through a strategy of license acquisitions as well as an internal research and development activity based on its prodrug technologies, Vectocell® and Tumor-Selective Prodrug (TSP).

blueKiwi Software SA specializes in providing enterprise social software tailored for financial firms, high-tech organizations, and professional services agencies. The company's flagship products include blueKiwi 2009, designed for people-centric organizations to foster social networks and collaborative environments among partners, customers, and colleagues, and blueKiwi Pro, which caters specifically to small and medium businesses. In addition to its software solutions, blueKiwi offers strategic consulting and technical services to enhance client operations. The company operates primarily in France and the United Kingdom.

ABIONYX Pharma SA is a French biopharmaceutical company established in 2005, currently based in Labege. It specializes in the discovery and development of therapies targeting high-density lipoprotein (HDL) for treating cardiovascular and metabolic diseases. The company's primary focus is on developing HDL mimetics to rapidly regress atherosclerotic plaque in high-risk patients. Its lead product candidate, CER-001, is a Phase II clinical trial asset designed to mimic the properties of pre-beta HDL for treating post-acute coronary syndrome patients and familial primary hypoalphalipoproteinemia patients. Additionally, ABIONYX Pharma has another drug candidate, CER-209, in Phase I trials for metabolic diseases and liver-related conditions such as atherosclerosis and non-alcoholic steato-hepatitis.

Domain Therapeutics SA is a biopharmaceutical company based in Illkirch-Graffenstaden, France, focused on the discovery and early development of therapeutic drugs targeting G protein-coupled receptors (GPCRs), which are key drug targets in various diseases. Founded in 2001, the company specializes in developing small molecules for the treatment of central nervous system (CNS) disorders and cancer. It employs its proprietary technology platform, DTect-All, which enables the identification of orthosteric and allosteric ligands, including Silent Allosteric Modulators (SAMs) that are challenging to discover using conventional methods. In addition, Domain Therapeutics offers BioSens-All, a platform to explore the signaling complexities associated with GPCR activation, enhancing its ability to address difficult targets, such as orphan and peptidic GPCRs.

Oxxius SA is a laser design and manufacturing company founded in 2002 and headquartered in Lannion, France. The company specializes in developing, designing, and producing diode-pumped solid-state lasers and laser diode modules across a range of wavelengths, from ultraviolet to near-infrared. Oxxius offers products that cater to various applications, including fluorescence analysis, interferometry, Raman spectroscopy, and non-destructive testing. Its innovative, patented solid-state laser architecture provides notable advancements in compactness, reliability, and cost-effectiveness, along with exceptional spectral and spatial beam characteristics. The company's laser solutions are utilized in sectors such as life sciences, analytics, and manufacturing, serving both research and industrial customers. Oxxius markets its products through a network of distributors across multiple countries, including the United States, Germany, China, and Japan, among others. Through its commitment to quality and customer service, Oxxius aims to drive disruptive innovations in the field of bio-photonics and related instrumentation.

Qosmos SA, founded in 2000 and headquartered in Paris, France, specializes in embedded deep packet inspection (DPI) technologies for internet protocol traffic classification and network intelligence. The company offers a range of solutions, including ixEngine, a comprehensive software development kit that provides tools for decoding, protocol plugins, and real-time traffic flow classification. Its technology is applicable in various domains such as lawful interception, network protection, regulatory compliance, and content-based billing. Qosmos also develops solutions for virtual network functions and provides application classification and metadata extraction tailored for telecommunications and enterprise developers. With a focus on transforming networks into intelligent information sources, Qosmos enables users to analyze data traffic while supporting applications ranging from security to performance optimization. The company maintains additional offices in London, Silicon Valley, Tokyo, and Singapore and operates as a subsidiary of Enea AB.

Varioptic SA, founded in 2002 and based in Lyon, France, specializes in the design and manufacture of adjustable lens solutions, particularly electrically controlled optical liquid lenses. The company offers a range of products including variable focus liquid lenses, autofocus lens modules, and microscope autofocus modules, which are utilized across various sectors such as industrial, biometrics, medical, and consumer applications. To ensure its technological leadership, Varioptic invests significantly in research and development, focusing on innovative products and advancements in optical technology. The company distributes its products through a network of distributors and operates as a subsidiary of Invenios France SAS.

Streamezzo S.A. is a Paris-based company that specializes in developing mobile media products and solutions tailored for telecom operators, broadcasters, media companies, content providers, and service providers. Founded in 2004, the company offers a comprehensive suite of products including the Rich Media Software Suite, which features tools for mobile users to access interactive services such as Mobile TV, widgets, and multimedia content. Its offerings encompass the Rich Media Client for accessing media services, the Rich Media Server for deploying these services, and an integrated multimedia authoring suite known as Workbench. Additionally, Streamezzo provides various solutions like Interactive Mobile TV, Music Jukebox for music downloads, and tools for mobile marketing and user engagement. The company also delivers professional services to assist clients in managing and customizing their mobile media offerings effectively.

Fovea Pharmaceuticals is a French biopharmaceutical company established in 2005, specializing in the discovery and development of drugs for ocular diseases. Based in Paris, Fovea focuses on creating innovative treatments for various eye conditions, including allergic conjunctivitis, hereditary angioedema, diabetic macular edema, and retinitis pigmentosa. The company's key products include FOV1101 Prednisporin, FOV2302, FOV2304, and FOV2501, which address a range of ocular disorders and associated complications. As of October 2009, Fovea operates as a subsidiary of Sanofi, enhancing its capabilities to deliver effective therapies for vision-related health issues.

ABIONYX Pharma SA is a French biopharmaceutical company established in 2005, currently based in Labege. It specializes in the discovery and development of therapies targeting high-density lipoprotein (HDL) for treating cardiovascular and metabolic diseases. The company's primary focus is on developing HDL mimetics to rapidly regress atherosclerotic plaque in high-risk patients. Its lead product candidate, CER-001, is a Phase II clinical trial asset designed to mimic the properties of pre-beta HDL for treating post-acute coronary syndrome patients and familial primary hypoalphalipoproteinemia patients. Additionally, ABIONYX Pharma has another drug candidate, CER-209, in Phase I trials for metabolic diseases and liver-related conditions such as atherosclerosis and non-alcoholic steato-hepatitis.

Filao publishes, develops, and distributes java based mobile games and java mobile gaming technologies for mass market mobile devices. It specializes in embedded java technologies, wireless games, and entertainment applications. The company serves mobile operators and PDA and handset manufacturers. It distributes its products through shipped, over the air, online, and specialized retail outlets. The company was founded in 2000 as InfraWorlds SA and changed its name to Filao in 2005. Filao is based in Paris, France. As of May 10, 2007, Filao is a subsidiary of Zenops SA.

Endotis discovers, develops, and manufactures cardiovascular therapeutics. The company also discovers and develops small-glyco drugs for applications in thrombosis, oncology, and hematology areas. Its portfolio of products includes EP217609, a neutralizable anti-coagulant for managing extracorporeal blood circulation during open-heart surgery; FondaParinux, an injectable drug for the prevention and treatment of venous thromboembolism; and an oral anti-coagulant for stroke prevention in atrial fibrillation. Endotis was founded in 2003 and is based in Romainville, France.

Sefas Innovation, founded in 1991 and headquartered in Paris, France, specializes in collaborative document composition and production software, primarily catering to Fortune 500 companies. With additional offices in the UK and the US, the company employs over 80 staff members worldwide. Sefas' flagship product, the Open Print software suite, is utilized by various sectors, including financial services, banking, insurance, utilities, telecommunications, and the public sector, for designing, composing, and producing complex business-to-consumer documents. Its unique capability to integrate data from multiple sources allows for the creation of personalized communications. Recently, Open Print has been increasingly adopted for redesigning mission-critical documents to incorporate marketing campaigns, thereby generating new revenue opportunities. The UK office, established in 1999 in Bristol, serves notable clients such as Nationwide and British Telecom, who have been utilizing Sefas' solutions since the early 2000s.

Filao publishes, develops, and distributes java based mobile games and java mobile gaming technologies for mass market mobile devices. It specializes in embedded java technologies, wireless games, and entertainment applications. The company serves mobile operators and PDA and handset manufacturers. It distributes its products through shipped, over the air, online, and specialized retail outlets. The company was founded in 2000 as InfraWorlds SA and changed its name to Filao in 2005. Filao is based in Paris, France. As of May 10, 2007, Filao is a subsidiary of Zenops SA.

VoluBill S.A. is a provider of real-time monitoring, control, and charging software tailored for communication providers. Founded in 2001 and based in Montbonnot Saint Martin, France, with additional offices in Europe and Asia, the company specializes in solutions for fixed, mobile, and fixed mobile convergent operators. VoluBill's product offerings include CHARGE-IT, which facilitates real-time on-the-network convergent charging and control for data services; CHARGE-IT Service Controller, a platform for network charging, control, and policy enforcement; and CHARGE-IT Dynamic Charging Platform, which supports various charging models such as pre-pay, post-pay, and now-pay for data services.

Sensitive Object SA is a company specializing in the development of electronic products and touch-interface technology. Founded in 2003 and headquartered in Boulogne Billancourt, France, with additional operations in Paris and Singapore, the company focuses on a diverse range of applications including touch screens, consumer electronics, computing, outdoor interactive solutions, access control, home automation, healthcare, industrial control, and interactive digital advertising. Its product offerings encompass touch screens, peripherals, and control panels designed to enhance user interaction across various industries.

Oxxius SA is a laser design and manufacturing company founded in 2002 and headquartered in Lannion, France. The company specializes in developing, designing, and producing diode-pumped solid-state lasers and laser diode modules across a range of wavelengths, from ultraviolet to near-infrared. Oxxius offers products that cater to various applications, including fluorescence analysis, interferometry, Raman spectroscopy, and non-destructive testing. Its innovative, patented solid-state laser architecture provides notable advancements in compactness, reliability, and cost-effectiveness, along with exceptional spectral and spatial beam characteristics. The company's laser solutions are utilized in sectors such as life sciences, analytics, and manufacturing, serving both research and industrial customers. Oxxius markets its products through a network of distributors across multiple countries, including the United States, Germany, China, and Japan, among others. Through its commitment to quality and customer service, Oxxius aims to drive disruptive innovations in the field of bio-photonics and related instrumentation.

Innate Pharma S.A. is a biotechnology company based in Marseille, France, focused on discovering and developing therapeutic antibodies for oncology and inflammatory diseases. The company specializes in first-in-class immunotherapy drug candidates that target receptors and pathways controlling innate immunity. Its product pipeline includes Monalizumab, an immune checkpoint inhibitor in Phase II trials for advanced solid tumors, and Lacutamab, an anti-KIR3DL2 antibody in Phase II trials for cutaneous T-cell lymphoma. Other notable candidates include IPH5201, a CD39-targeting antibody in Phase I trials, and IPH5301, a CD73-blocking antibody in preclinical development. Innate Pharma utilizes its proprietary ANKET platform to create innovative therapies and has established licensing and collaboration agreements with major pharmaceutical companies. Founded in 1999, Innate Pharma continues to advance its mission of harnessing the innate immune system to improve cancer treatment outcomes.

Domain Therapeutics SA is a biopharmaceutical company based in Illkirch-Graffenstaden, France, focused on the discovery and early development of therapeutic drugs targeting G protein-coupled receptors (GPCRs), which are key drug targets in various diseases. Founded in 2001, the company specializes in developing small molecules for the treatment of central nervous system (CNS) disorders and cancer. It employs its proprietary technology platform, DTect-All, which enables the identification of orthosteric and allosteric ligands, including Silent Allosteric Modulators (SAMs) that are challenging to discover using conventional methods. In addition, Domain Therapeutics offers BioSens-All, a platform to explore the signaling complexities associated with GPCR activation, enhancing its ability to address difficult targets, such as orphan and peptidic GPCRs.

Varioptic SA, founded in 2002 and based in Lyon, France, specializes in the design and manufacture of adjustable lens solutions, particularly electrically controlled optical liquid lenses. The company offers a range of products including variable focus liquid lenses, autofocus lens modules, and microscope autofocus modules, which are utilized across various sectors such as industrial, biometrics, medical, and consumer applications. To ensure its technological leadership, Varioptic invests significantly in research and development, focusing on innovative products and advancements in optical technology. The company distributes its products through a network of distributors and operates as a subsidiary of Invenios France SAS.

InfraWorlds is an innovative French startup specializing in embedded Java technologies and solutions for wireless phones. Its technological competencies, coupled with unrivalled graphic creativity, have earned the company a solid reputation among the main players in this booming sector. Built around a team of dedicated professionals, which is soon to be expanded, InfraWorlds is today consolidating its lead in the fast-growing global wireless entertainment market.

Varioptic SA, founded in 2002 and based in Lyon, France, specializes in the design and manufacture of adjustable lens solutions, particularly electrically controlled optical liquid lenses. The company offers a range of products including variable focus liquid lenses, autofocus lens modules, and microscope autofocus modules, which are utilized across various sectors such as industrial, biometrics, medical, and consumer applications. To ensure its technological leadership, Varioptic invests significantly in research and development, focusing on innovative products and advancements in optical technology. The company distributes its products through a network of distributors and operates as a subsidiary of Invenios France SAS.

Domain Therapeutics SA is a biopharmaceutical company based in Illkirch-Graffenstaden, France, focused on the discovery and early development of therapeutic drugs targeting G protein-coupled receptors (GPCRs), which are key drug targets in various diseases. Founded in 2001, the company specializes in developing small molecules for the treatment of central nervous system (CNS) disorders and cancer. It employs its proprietary technology platform, DTect-All, which enables the identification of orthosteric and allosteric ligands, including Silent Allosteric Modulators (SAMs) that are challenging to discover using conventional methods. In addition, Domain Therapeutics offers BioSens-All, a platform to explore the signaling complexities associated with GPCR activation, enhancing its ability to address difficult targets, such as orphan and peptidic GPCRs.

Innate Pharma S.A. is a biotechnology company based in Marseille, France, focused on discovering and developing therapeutic antibodies for oncology and inflammatory diseases. The company specializes in first-in-class immunotherapy drug candidates that target receptors and pathways controlling innate immunity. Its product pipeline includes Monalizumab, an immune checkpoint inhibitor in Phase II trials for advanced solid tumors, and Lacutamab, an anti-KIR3DL2 antibody in Phase II trials for cutaneous T-cell lymphoma. Other notable candidates include IPH5201, a CD39-targeting antibody in Phase I trials, and IPH5301, a CD73-blocking antibody in preclinical development. Innate Pharma utilizes its proprietary ANKET platform to create innovative therapies and has established licensing and collaboration agreements with major pharmaceutical companies. Founded in 1999, Innate Pharma continues to advance its mission of harnessing the innate immune system to improve cancer treatment outcomes.

Innate Pharma S.A. is a biotechnology company based in Marseille, France, focused on discovering and developing therapeutic antibodies for oncology and inflammatory diseases. The company specializes in first-in-class immunotherapy drug candidates that target receptors and pathways controlling innate immunity. Its product pipeline includes Monalizumab, an immune checkpoint inhibitor in Phase II trials for advanced solid tumors, and Lacutamab, an anti-KIR3DL2 antibody in Phase II trials for cutaneous T-cell lymphoma. Other notable candidates include IPH5201, a CD39-targeting antibody in Phase I trials, and IPH5301, a CD73-blocking antibody in preclinical development. Innate Pharma utilizes its proprietary ANKET platform to create innovative therapies and has established licensing and collaboration agreements with major pharmaceutical companies. Founded in 1999, Innate Pharma continues to advance its mission of harnessing the innate immune system to improve cancer treatment outcomes.

Established in France in 1989, BoostWorks, Inc. is known worldwide for its creative, high-quality, award-winning network acceleration solutions. Now headquartered in San Francisco, BoostWorks offers a suite of products that immediately solve performance problems experienced by remote users of browser-based applications, without burdening your IT staff or changing your application software infrastructure. This helps global enterprise networks perform faster and more efficiently than ever before. Our products deliver back to your remote users the kind of performance they expect from your wide-area network. BoostWorks' products are sold through its direct sales force, leading systems integrators, distributors, and software vendors with whom it has established worldwide strategic alliances.

Established in France in 1989, BoostWorks, Inc. is known worldwide for its creative, high-quality, award-winning network acceleration solutions. Now headquartered in San Francisco, BoostWorks offers a suite of products that immediately solve performance problems experienced by remote users of browser-based applications, without burdening your IT staff or changing your application software infrastructure. This helps global enterprise networks perform faster and more efficiently than ever before. Our products deliver back to your remote users the kind of performance they expect from your wide-area network. BoostWorks' products are sold through its direct sales force, leading systems integrators, distributors, and software vendors with whom it has established worldwide strategic alliances.